Marc Peter Bonaca MD, MPH, FACC, FAHA

Dr. Marc Bonaca is a cardiologist and vascular medicine specialist serving as Executive Director of the Colorado Prevention Center (CPC) and Director of Vascular Research and Professor of Medicine at the University of Colorado Anschutz. Professor Bonaca is also a faculty member at Brigham and Women’s Hospital and Harvard Medical School and has served as an investigator at the TIMI Study Group. Professor Bonaca directed pharmacovigilance at TIMI and was an investigator on several large outcomes trials, including TRA2P-TIMI 50, PEGASUS-TIMI 54, DECLARE-TIMI 58, and REAL TIMI 63B. Professor Bonaca has published peripheral artery disease population data and limb outcome data from TRA2P-TIMI 50, ENGAGE-TIMI 48, PEGASUS-TIMI 54, and DECLARE-TIMI 58, among others.

Professor Bonaca’s research focuses on ischaemic risk with atherosclerotic vascular disease, risk prediction, and risk modification using pharmacologic and biologic therapies. Professor Bonaca has extensive experience designing and conducting large, multicentre randomised clinical trials, as well as analysing registries and real-world datasets. Professor Bonaca’s areas of interest include peripheral artery disease, peripheral vascular disease, and diabetes, with a focus on the breadth of risk, including ischemic limb outcomes, microvascular complications, and major adverse cardiovascular events. Professor Bonaca is also investigating the cardiac, vascular, and thrombotic complications associated with novel oncologic therapies. At CPC, he has focused on building a robust faculty and operational group dedicated to high-quality, efficient trials leveraging health networks, informatics, and decentralised design.